Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2011 October;170(5) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2011 October;170(5):327-31

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE

A Journal on Internal Medicine and Pharmacology


Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index

 

REVIEWS  


Gazzetta Medica Italiana Archivio per le Scienze Mediche 2011 October;170(5):327-31

language: Italian

Vernakalant: a new drug for the treatment of atrial fibrillation

Incardona V. M., Dato E., Dato A. G.

Centro di Diagnostica Cardiovascolare del Dott. Dato Achille Giuseppe & C. s.a.s., Paternò, Italia


PDF  


Vernakalant (RSD1235) is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific channels: the Kv1.5 channel which carries IK(ur), and the Kir3.1/3.4 channel which carries IK(Ach). Vernakalant can to block Ito, late Ina, with minor blockade of IKr currents. Vernakalant is available in intravenous forms and in oral forms. In phase II and III trials, intravenous vernakalant has been shown to be effective in terminating acute onset atrial fibrillation (AF) whose duration is longer than 3 hours and shorter than 7 days. Studies to date have shown that 51% of patients were able to maintain sinus rhythm after 90 days of using oral vernakalant 50 mg/kg twice daily compared with 37% of patients receiving placebo. Vernakalant appears to be a safe drug to use, with a few side-effects being dysgeusia, paresthesias, nausea but a minimal frequency of ventricular arrhythmias.

top of page

Publication History

Cite this article as

Corresponding author e-mail